newsfilter
← Latest News
GlobeNewswire·

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track for IND